title: Iterative optimization of high-affinity proteases inhibitors using phage display. 1. Plasmin.
abstract: We generated a series of libraries having variants of the first Kunitz domain of human lipoprotein-associated coagulation inhibitor (LACI-D1, also known as tissue-factor pathway inhibitor-I) displayed on bacteriophage M13 as pIII-fusions. We varied LACI-DI iteratively in two regions: the P1 region (positions 10-21) and the "second loop", (positions 31-39), which together form one end of the domain. Display-phage library Lib#1 allows 31 200 amino-acid sequences in P1 region (residues 13, 16-19). Preliminary, we screened Lib#1 against human plasmin (PLA, EC 3.4.21.7) immobolized on agarose to enrich for phage displaying variants with PLA affinity. We introduced a 1600-fold increase in second-loop diversity (residues 31, 32, 34, 39) into the population of selectants from Lib#1, yielding Lib#2. Lib#2 (allowing approximately 50 million amino-acid sequences) was screened against PLA-agarose to isolate highest affinity binders. Protein EPI-P211, derived from the best isolate of Lib#2, inhibits PLA with Ki = 2 nM (at least 500-fold better than LACI-D1) and with high specificity. We used amino-acid sequences of PLA-binding selectants to design a PLA-biased library (Lib#3) which we screened against PLA. The protein EPI-P302 (derived from the best binder obtained from Lib#3) has Ki for PLA inhibition of 87 pM, which is 25-fold better than the first-round best binder and > or = 12 500-fold better than LACI-D1. EPI-P302 also shows very high specificity for PLA vs other human proteases and is resistant to inactivation by oxidants and extremes of temperature or pH. Thus, one can use selectants from one library to design target-tailored combinatorial libraries and obtain quite stable, highly specific, very high-affinity binding molecules while maintaining an essentially human framework.
authors.affiliation: Protein Engineering Corporation, Cambridge, Massachusetts 02138, USA.
authors.forename: W
authors.initials: W
authors.lastname: Markland
authors.forename: A C
authors.initials: AC
authors.lastname: Ley
authors.forename: S W
authors.initials: SW
authors.lastname: Lee
authors.forename: R C
authors.initials: RC
authors.lastname: Ladner
mesh_terms: D000595:Amino Acid Sequence; D007611:Aprotinin / Q000737:chemistry*; D017104:Bacteriophage M13; D001483:Base Sequence; D005341:Fibrinolysin / Q000037:antagonists & inhibitors*; D015723:Gene Library; D014644:Genetic Variation; D006801:Humans; D008074:Lipoproteins / Q000096:biosynthesis* / Q000737:chemistry* / Q000494:pharmacology; D008961:Models, Structural; D008969:Molecular Sequence Data; D016254:Mutagenesis, Insertional; D017433:Protein Structure, Secondary; D015183:Restriction Mapping; D017386:Sequence Homology, Amino Acid; D015842:Serine Proteinase Inhibitors / Q000096:biosynthesis* / Q000737:chemistry* / Q000494:pharmacology; D013917:Thrombin / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D008074:Lipoproteins; D015842:Serine Proteinase Inhibitors; C051928:lipoprotein-associated coagulation inhibitor; D007611:Aprotinin; D013917:Thrombin; D005341:Fibrinolysin